Eli Lilly’s Mounjaro cuts risk of developing Type 2 diabetes, study finds

By / / Finance / 1 minute of reading




Eli Lilly’s stock gained more than 2% premarket on Tuesday after the drugmaker said that tirzepatide, marketed as the diabetes drug Mounjaro and weight-loss treatment Zepbound, sharply cut patients’ risk of developing Type 2 diabetes in a late-stage trial.



Source link

About The Author

Avatar of Lisa Ferguson
Lisa Ferguson is an award-winning writer and editor who is passionate about politics, health, business, and finance. In her free time, Lisa loves to read nonfiction books and watch documentaries about current affairs. Her favorite subjects are health care policy, climate change, and social justice issues like immigration reform.

Start typing and press enter to search

Scroll to Top